FOXP3 and non-small cell lung carcinoma: A similar study of 196 NSCLC patients found improved overall survival for patients with increased tumor-infiltrating CD8+ T-cells, but poorer overall survival for patients with increased tumor-infiltrating FoxP3+ Tregs (53).